Elevated neuron-specific enolase level is associated with postoperative delirium and detection of phosphorylated neurofilament heavy subunit: A prospective observational study.
Aged
Aged, 80 and over
Area Under Curve
Biomarkers
/ blood
Delirium
/ diagnosis
Female
Humans
Male
Middle Aged
Neurofilament Proteins
/ blood
Phosphopyruvate Hydratase
/ blood
Phosphorylation
Postoperative Period
Prospective Studies
Protein Subunits
/ blood
ROC Curve
S100 Calcium Binding Protein beta Subunit
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
07
2021
accepted:
14
10
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Delirium is the most common central nervous system complication after surgery. Detection of phosphorylated neurofilament heavy subunit in the serum reflects axonal damage within the central cervous system and is associated with the severity of postoperative delirium. Neuron-specific enolase and S100 calcium-binding protein β have been identified as possible serum biomarkers of postoperative delirium. This study examined the association of the levels of these markers with incidence of postoperative delirium and detection of phosphorylated neurofilament heavy subunit. This study represents a post hoc analysis of 117 patients who participated in a prospective observational study of postoperative delirium in patients undergoing cancer surgery. Patients were clinically assessed for development of postoperative delirium within the first five days of surgery. Serum levels of phosphorylated neurofilament heavy subunit, neuron-specific enolase, and S100 calcium-binding protein β levels were measured on postoperative day 3. Forty-one patients (35%) were clinically diagnosed with postoperative delirium. Neuron-specific enolase level (P < 0.0001) and the proportion of patients positive for phosphorylated neurofilament heavy subunit (P < 0.0001) were significantly higher in the group of patients with postoperative delirium. Neuron-specific enolase level discriminated between patients with and without clinically diagnosed postoperative delirium with significantly high accuracy (area under the curve [AUC], 0.87; 95% confidence interval [CI], 0.79-0.95; P < 0.0001). Neuron-specific enolase level was associated with incidence of postoperative delirium independently of age (adjusted odds ratio, 8.291; 95% Cl, 3.506-33.286; P < 0.0001). The AUC for the serum neuron-specific enolase level in detecting phosphorylated neurofilament heavy subunit was significant (AUC, 0.78; 95% CI, 0.66-0.90; P < 0.0001). Elevated serum neuron-specific enolase was associated with postoperative delirium independent of age as well as detection of phosphorylated neurofilament heavy subunit in serum. Serum neuron-specific enolase and phosphorylated neurofilament heavy subunit might be useful as biomarkers of postoperative delirium. University Medical Information Network (UMIN) trial ID: UMIN000010329; https://clinicaltrials.gov/.
Sections du résumé
BACKGROUND
Delirium is the most common central nervous system complication after surgery. Detection of phosphorylated neurofilament heavy subunit in the serum reflects axonal damage within the central cervous system and is associated with the severity of postoperative delirium. Neuron-specific enolase and S100 calcium-binding protein β have been identified as possible serum biomarkers of postoperative delirium. This study examined the association of the levels of these markers with incidence of postoperative delirium and detection of phosphorylated neurofilament heavy subunit.
METHODS
This study represents a post hoc analysis of 117 patients who participated in a prospective observational study of postoperative delirium in patients undergoing cancer surgery. Patients were clinically assessed for development of postoperative delirium within the first five days of surgery. Serum levels of phosphorylated neurofilament heavy subunit, neuron-specific enolase, and S100 calcium-binding protein β levels were measured on postoperative day 3.
RESULTS
Forty-one patients (35%) were clinically diagnosed with postoperative delirium. Neuron-specific enolase level (P < 0.0001) and the proportion of patients positive for phosphorylated neurofilament heavy subunit (P < 0.0001) were significantly higher in the group of patients with postoperative delirium. Neuron-specific enolase level discriminated between patients with and without clinically diagnosed postoperative delirium with significantly high accuracy (area under the curve [AUC], 0.87; 95% confidence interval [CI], 0.79-0.95; P < 0.0001). Neuron-specific enolase level was associated with incidence of postoperative delirium independently of age (adjusted odds ratio, 8.291; 95% Cl, 3.506-33.286; P < 0.0001). The AUC for the serum neuron-specific enolase level in detecting phosphorylated neurofilament heavy subunit was significant (AUC, 0.78; 95% CI, 0.66-0.90; P < 0.0001).
CONCLUSION
Elevated serum neuron-specific enolase was associated with postoperative delirium independent of age as well as detection of phosphorylated neurofilament heavy subunit in serum. Serum neuron-specific enolase and phosphorylated neurofilament heavy subunit might be useful as biomarkers of postoperative delirium.
TRIAL REGISTRATION
University Medical Information Network (UMIN) trial ID: UMIN000010329; https://clinicaltrials.gov/.
Identifiants
pubmed: 34797829
doi: 10.1371/journal.pone.0259217
pii: PONE-D-21-24158
pmc: PMC8604326
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
Protein Subunits
0
S100 Calcium Binding Protein beta Subunit
0
ENO2 protein, human
EC 4.2.1.11
Phosphopyruvate Hydratase
EC 4.2.1.11
Banques de données
UMIN-CTR
['UMIN000010329']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0259217Déclaration de conflit d'intérêts
The Department of Pain and Palliative Medical Sciences, where M. Hasegawa-Moriyama works, is sponsored by Shionogi Co., Ltd. (Osaka, Japan) and Nippon Zoki Pharmaceutical Co., Ltd. (Osaka, Japan). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Crit Care Med. 2009 Jun;37(6):1881-5
pubmed: 19384206
Crit Care Med. 2007 Dec;35(12):2721-4; quiz 2725
pubmed: 18074477
Crit Care Med. 2004 Apr;32(4):955-62
pubmed: 15071384
Nat Rev Cancer. 2007 Mar;7(3):192-201
pubmed: 17318212
Anesthesiology. 2012 Mar;116(3):603-12
pubmed: 22293721
Methods Mol Biol. 2014;1105:43-57
pubmed: 24623218
Acta Neurochir (Wien). 2017 Feb;159(2):209-225
pubmed: 27957604
PLoS One. 2019 Oct 1;14(10):e0222721
pubmed: 31574089
Br J Anaesth. 2020 Oct;125(4):492-504
pubmed: 32798069
Biometrics. 2014 Mar;70(1):212-23
pubmed: 24261514
Crit Care Med. 2001 Jul;29(7):1370-9
pubmed: 11445689
Br J Anaesth. 2000 Feb;84(2):242-4
pubmed: 10743460
BMC Geriatr. 2014 Aug 28;14:96
pubmed: 25168927
J Neurol Sci. 2012 Oct 15;321(1-2):39-42
pubmed: 22863291
Biomedicines. 2021 May 15;9(5):
pubmed: 34063403
Intensive Care Med. 2001 Dec;27(12):1892-900
pubmed: 11797025
BMC Anesthesiol. 2020 Sep 28;20(1):246
pubmed: 32988381
Neurosci Lett. 2002 Mar 8;320(3):156-60
pubmed: 11852185
Clin Cancer Res. 2015 Mar 15;21(6):1348-52
pubmed: 25589615
Spinal Cord. 2012 Jul;50(7):493-6
pubmed: 22270191
Ann Intensive Care. 2019 Jul 1;9(1):76
pubmed: 31263968
Lancet. 2014 Mar 8;383(9920):911-22
pubmed: 23992774
Neurosci Lett. 2017 Jul 13;653:39-44
pubmed: 28504118
Immunity. 2014 Nov 20;41(5):694-707
pubmed: 25517612
Eur Spine J. 2018 Aug;27(8):1824-1830
pubmed: 29557051
Crit Care Med. 2012 Jul;40(7):2022-32
pubmed: 22710202
Curr Opin Anaesthesiol. 2014 Apr;27(2):117-22
pubmed: 24514034
EBioMedicine. 2018 Nov;37:547-556
pubmed: 30348620
Eur J Cardiothorac Surg. 1999 Nov;16(5):513-8
pubmed: 10609901